Holen Sie sich die Stockscreener-App
0.6838
4.75%
-0.0341
Vorhandelsmarkt:
.68
-0.0038
-0.56%
Schlusskurs vom Vortag:
$0.7179
Offen:
$0.757
24-Stunden-Volumen:
5.53M
Relative Volume:
1.31
Marktkapitalisierung:
$84.47M
Einnahmen:
$36.86M
Nettoeinkommen (Verlust:
$-171.67M
KGV:
-0.4559
EPS:
-1.5
Netto-Cashflow:
$-171.05M
1W Leistung:
+7.40%
1M Leistung:
-49.72%
6M Leistung:
-54.72%
1J Leistung:
-81.34%
1-Tages-Spanne:
$0.6783
$0.8178
1-Wochen-Bereich:
$0.5561
$0.8178
52-Wochen-Spanne:
$0.4913
$6.2801
Mersana Therapeutics Inc Stock (MRSN) Company Profile
Firmenname
Mersana Therapeutics Inc
Sektor
Branche
Telefon
617-498-0020
Adresse
840 MEMORIAL DRIVE, CAMBRIDGE
Vergleichen Sie MRSN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
0.6838 | 84.47M | 36.86M | -171.67M | -171.05M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-15 | Fortgesetzt | Citigroup | Buy |
| 2024-03-19 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-02-29 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-02-29 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-02-29 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-12-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-07-28 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-07-27 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-07-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-07-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-07-27 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-07-27 | Herabstufung | Truist | Buy → Hold |
| 2023-07-27 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-06-16 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-06-15 | Eingeleitet | Guggenheim | Buy |
| 2023-03-16 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-20 | Eingeleitet | Citigroup | Buy |
| 2022-11-21 | Eingeleitet | Truist | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-08-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-31 | Eingeleitet | Credit Suisse | Neutral |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-04-29 | Eingeleitet | BTIG Research | Buy |
| 2020-01-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-11-14 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2018-05-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-03-19 | Herabstufung | JP Morgan | Overweight → Neutral |
Alle ansehen
Mersana Therapeutics Inc Aktie (MRSN) Neueste Nachrichten
William Blair Initiates Coverage of Mersana Therapeutics (MRSN) with Outperform Recommendation - MSN
Mersana initiated at outperform at William Blair on antibody-drug conjugate potential - Seeking Alpha
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
William Blair starts Mersana stock with Outperform rating - MSN
Mersana Therapeutics Inc [MRSN] Shares Rise 18.66 % on Wednesday - Knox Daily
Mersana Therapeutics Updates Investor Presentation Online - TipRanks
Investors in cash trouble should check out Mersana Therapeutics Inc (MRSN) - SETE News
MRSNMersana Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference - GlobeNewswire
Exclusive: Mersana Therapeutics CEO to Reveal ADC Pipeline Updates at Guggenheim Conference - StockTitan
Apple Swings to Outperformer: Is It a Buy Ahead of Earnings? - The Globe and Mail
MRSN News Today | Why did Mersana Therapeutics stock go down today? - MarketBeat
Brokerages Set Mersana Therapeutics, Inc. (NASDAQ:MRSN) PT at $5.57 - MarketBeat
MRSN stock touches 52-week low at $0.56 amid market challenges - MSN
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $5.57 Average Price Target from Analysts - MarketBeat
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
MRSN stock touches 52-week low at $0.56 amid market challenges By Investing.com - Investing.com South Africa
Mersana Therapeutics' SVP sells shares worth $4,912 - MSN
Mersana Therapeutics chief development officer sells shares worth $3,444 - MSN
Mersana Therapeutics CEO sells $2,618 in stock - MSN
Mersana Therapeutics' chief accounting officer sells shares worth $2,061 - MSN
Mersana Therapeutics officer Timothy Lowinger sells $4,667 in stock - MSN
Mersana Therapeutics officer Timothy Lowinger sells $4,667 in stock By Investing.com - Investing.com South Africa
Mersana Therapeutics SVP sells $2,955 in stock By Investing.com - Investing.com South Africa
Mersana Therapeutics' chief accounting officer sells shares worth $2,061 By Investing.com - Investing.com Australia
Mersana Therapeutics CEO sells $2,618 in stock By Investing.com - Investing.com Australia
Mersana Therapeutics' SVP sells shares worth $4,912 By Investing.com - Investing.com South Africa
Mersana Therapeutics SVP sells $2,955 in stock - MSN
Mersana therapeutics VP Mandelia sells $1,128 in stock - MSN
Mersana therapeutics' chief officer sells shares worth $1,130 - MSN
JPMorgan Chase & Co. Grows Stock Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Mersana therapeutics director Anna Protopapas sells shares worth $5,009 - MSN
Mersana Therapeutics’ chief accounting officer sells shares worth $2,061 By Investing.com - Investing.com Nigeria
Mersana Therapeutics chief development officer sells shares worth $3,444 By Investing.com - Investing.com South Africa
Mersana therapeutics director Anna Protopapas sells shares worth $5,009 By Investing.com - Investing.com Canada
Finanzdaten der Mersana Therapeutics Inc-Aktie (MRSN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.82%
0.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):